Free Newsletter
Survey says: Nissen or Rost for FDA Commish
Steven Nissen (photo) may be on Big Pharma's short list for the least desirable candidate for FDA Commissioner, but many apparently think its critics like him who should be at the top of the list. That's according to a survey conducted by Pharma Marketing News. Nearly 500 respondents weighed in with their picks for who should be nominated as FDA Commissioner. The survey asked for opinions for 10 potentials usually mentioned in the media. Peter Rost took first place, Steven Nissen came in at second, with Susan Wood in third. Janet Woodcock and Robert Califf tied for fourth place.
Survey respondents included pharma industry execs and staff, agents and vendors to the industry, healthcare professionals, government staff and readers from the general public. Interestingly, although Rost was favored overall, Nissen was favored among US respondents. But broken down by industry, the results showed that Pharma in particular favored FDA insiders Woodcock and David Kessler, while healthcare professionals supported Nissen and the general public preferred Rost.
- check out the Pharma Marketing News post
- view the survey results (.pdf)
Related Articles:
FDA chief to step down as Obama's sworn in
Add ex-Waxmanite to FDA hopefuls list
Should Kessler return to FDA?
Sweep the FDA clean, Stupak says
Sharfstein looks to be on FDA short list
Who will take over at the FDA, HHS?
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: